


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A composition comprising a fused pyrrolocarbazole with the formula:



at least about 20% (w/w) of a polyoxyl stearate; and at least one polyethylene glycol.

2. (Original) The composition of claim 1 wherein the fused pyrrolocarbazole is present at a concentration of about 1 to about 100 mg/mL.
3. (Original) The composition of claim 2 wherein the fused pyrrolocarbazole is present at a concentration of about 1 to about 50 mg/mL.
4. (Canceled)
5. (Canceled)

6. (Currently Amended) The composition of claim 1 wherein the polyethylene glycol has a molecular weight from about 300 to about 8000 Daltons.
7. (Currently Amended) The composition of claim 6 wherein the polyethylene glycol has a molecular weight from about 400 to about 3350 Daltons.
8. (Currently Amended) The composition of claim 7 wherein the polyethylene glycol has a molecular weight from about 400 to about 1500 Daltons.
9. (Previously Presented) The composition of claim 1 wherein the polyethylene glycol is selected from PEG-400, PEG-600, PEG-1000, and PEG-1450.
10. (Cancelled)
11. (Currently Amended) The composition of claim 9 wherein the ratio of polyethylene glycol:polyoxyl stearate ranges from about 50:50 to about 80:20.
12. (Currently Amended) The composition of claim 11 wherein the ratio of polyethylene glycol:polyoxyl stearate is about 50:50.
13. (Currently Amended) The composition of claim 11 wherein the ratio of polyethylene glycol:polyoxyl stearate is about 80:20.
14. (Original) The composition of claim 1 comprising a polyethylene glycol mixture selected from PEG-400/PEG-1000, PEG-400/PEG-1450, PEG-600/PEG-1000, and PEG-600/PEG-1450.

15. (Currently Amended) The composition of claim 14 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is from about 50:50 to about 80:20.
16. (Currently Amended) The composition of claim 15 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is about 50:50.
17. (Currently Amended) The composition of claim 15 wherein the ratio of the polyethylene glycol mixture:polyoxyl stearate is about 80:20.
18. (Currently Amended) The composition of claim 16 wherein the composition comprises PEG-400:PEG-1000:polyoxyl stearate in a ratio of about 25:25:50.
19. (Currently Amended) The composition of claim 16 wherein the composition comprises PEG-400:PEG-1450:polyoxyl stearate in a ratio of about 25:25:50.
20. (Currently Amended) The composition of claim 17 wherein the composition comprises PEG-400:PEG-1000:polyoxyl stearate in a ratio of about 40:40:20.
21. (Currently Amended) The composition of claim 17 wherein the composition comprises PEG-400:PEG-1450:polyoxyl stearate in a ratio of about 40:40:20.
22. (Withdrawn and currently amended) A method of treating a disease or disorder in a mammal, comprising administering a composition of ~~claims~~ claim 1, ~~12, or 19~~ to a subject in need thereof.
23. (Withdrawn) The method of claim 22 wherein the disorder is a neurological disorder.
24. (Withdrawn) The method of claim 22 wherein the disorder is cancer.

DOCKET NO.: CP185B

PATENT

Application No.: 10/718,077

Notice of Allowance dated: January 14, 2010

25. (Withdrawn) The method of claim 24 wherein the cancer is prostate cancer.

26. (Withdrawn) The method of claim 24 wherein the cancer is acute myelogenous leukemia.

Claims 27 – 46 (Cancelled)

47. (New) The composition of claim 9 wherein the polyoxyl stearate is polyoxyethylene (40) stearate.

48. (New) The composition of claim 15 wherein the polyoxyl stearate is polyoxyethylene (40) stearate.